R
Repertoire Immune Medicines
Developing a new category of immune therapies for cancer, autoimmunity and infectious disease
About Repertoire Immune Medicines
Repertoire Immune Medicines is a biotechnology company operating in the healthcare and immunology sectors, focused on understanding and leveraging the human immune system to develop precise, immune-targeted therapies. The company was formed in 2020 through the merger of two Flagship Pioneering–founded ventures, Cogen Immune Medicines and Torque Therapeutics, combining complementary technologies in immune decoding and cellular immunotherapy.
Read full description
Repertoire’s work centers on cellular immunity, particularly the interactions between antigens and T-cell receptors (TCRs). By studying immune synapses at scale, the company aims to identify and engineer therapeutic immune responses that can be applied across diseases such as cancer, autoimmune disorders, and infectious diseases. Its approach integrates experimental biology with computational analysis to map immune recognition and translate those insights into drug candidates.
Operating within the biotechnology market, Repertoire’s business model is based on the research, development, and eventual commercialization of novel immune medicines. These therapies are designed to harness or redirect the body’s own T cells to achieve more targeted and effective disease treatment. In addition to product development, the company may pursue collaborations, licensing arrangements, or partnerships with pharmaceutical companies to advance its programs.
Revenue generation is expected to come primarily from the development and sale of proprietary immune-based therapeutics, with potential supplemental income from strategic partnerships and research collaborations typical of the biotech industry.
At a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Cambridge, United States
- Employees
- 85
- Open positions
- 5
- Dealroom signal
- 72.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Rumoured $1B, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 3 companies, latest Oct 2020
- Capital deployed
- —
- Preferred round
- MERGER
Latest news
Press, funding announcements and product moves mentioning Repertoire Immune Medicines.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Apr 2021 | $189M | $756M | Invus · Flagship Pioneering · PSP Investments · SoftBank | — |
| EARLY VCOther financing | Mar 2020 | $0 | — | JDRF T1D Fund | ↗ |
Growth signals
Latest recorded traffic for Repertoire Immune Medicines is 7.6K monthly website visits, up 55.1% over the last three months. Repertoire Immune Medicines's team declined 5.6% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
TeptheraBasel, SwitzerlandBiotechnology firm advancing precision immune medicines to treat cancer, autoimmune, and infectious diseases through TCR antigen discovery
→
CM
Cogen Immune MedicinesCambridge, United StatesDecodes antigen–T cell receptor interactions to enable discovery and design of immune-targeted therapeutics
→
Torque TherapeuticsCambridge, United StatesImmunotherapies to address cancers focused on the specific modulation of immune cell subsets
$100Mvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
JDRF T1D Fund
Invus
Flagship Pioneering
PSP Investments
SoftBank
Alaska Permanent Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Repertoire Immune Medicines on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Repertoire Immune Medicines’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.